miRNA Plasmid Composition for Kinase Expression Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Over-expression or mis-expression of kinases leads to homeostasis disruption and associated diseases, necessitating therapies to regulate gene expression and suppress the production of these bioactive molecules.
Innovation Solution
Compositions comprising plasmids that encode for microRNA (miRNA) sequences, which are complementary to target mRNA, are administered to upregulate miRNA production, leading to degradation or inactivation of target biomolecules such as cytokines and kinases, thereby reducing their bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If kinases are over-expressed or mis-expressed, then bioactive molecules are produced in excess, but homeostasis is lost and disease occurs
Solution Approach 1:
The patent extracts the regulatory function from the kinases themselves and places it in separate miRNA molecules. These miRNAs are designed to specifically target and degrade kinase mRNA, thereby removing the harmful over-expression while preserving the normal regulatory mechanisms through the miRNA-mediated degradation pathway.
Solution Approach 2:
The patent introduces miRNA as an intermediary substance between the kinase genes and their protein products. These miRNAs act as molecular brakes that regulate kinase expression levels by binding to kinase mRNA and preventing its translation or promoting its degradation, thus mediating the balance between production and homeostasis.
2Reliability
If therapies are developed to regulate gene expression and suppress bioactive molecules, then homeostasis can be restored, but the complexity of the therapeutic system increases
Solution Approach 1:
The patent uses synthetic miRNA sequences that are copies of natural miRNA structures. These artificial miRNAs are designed to mimic the function of endogenous regulatory molecules while providing specific targeting capability against pathogenic kinases. The miRNAs are encoded in plasmid vectors that can be delivered to cells, where they are processed into functional miRNA molecules that exert their regulatory effect.
Solution Approach 2:
The patent modifies the expression parameters of kinase genes by introducing miRNA that changes the mRNA stability and translation efficiency. The miRNAs alter key parameters such as mRNA half-life, translation rate, and protein folding, thereby controlling kinase production levels without affecting the underlying gene structure or requiring complex protein-based therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate the expression of target biomolecules, such as IL-1beta, IL-18, IL-6, IL-17A, interferon gamma, IL-2, IL-4, IL-5, IL-10, and IL-22, by increasing endogenous miRNA production, thus ameliorating the associated diseases.
Implementation Method 1
The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule
Implementation Method 2
the miRNA can cause the bioavailability of the target mRNA to decrease because it is degraded or inactivated by the miRNA
Data Source
AI summary
The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a kinase.